The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

Objective

The authors analyzed prescribing for antidepressant medications during 27,328 prenatal visits in ambulatory settings in the United States between 2002 and 2010.

Methods

Data from the 2002–2010 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey were used to compare prescribing for antidepressant medication during visits for outpatient prenatal care between 2002–2006 and 2007–2010.

Results

Prenatal visits associated with a prescription for an antidepressant increased from .7% in 2002–2006 to 2.1% in 2007–2010 (p<.01). The proportion of prescriptions for selective serotonin reuptake inhibitors (SSRIs) declined (from 87% to 66%, p=.04), particularly for paroxetine (from 19% to <1%, p<.01).

Conclusions

Despite controversy over possible negative effects, prescribing of antidepressants during pregnancy increased between 2002 and 2010. SSRIs represented a smaller proportion of all antidepressants prescribed, and prescribing of paroxetine, likely in response to warnings by the U.S. Food and Drug Administration, dropped dramatically.